Semaglutide Dosing and Management for Diabetes and Weight Loss

Dosing Regimens

For patients with type 2 diabetes, the American College of Cardiology recommends a semaglutide dosing regimen starting at 0.25 mg weekly, increasing to 1 mg weekly as needed for glycemic control, with no dosage adjustments required for patients with renal impairment 1, 2
For weight management, a titration schedule starting with 0.25 mg subcutaneously once weekly for 4 weeks, increasing to 0.5 mg, 1.0 mg, and 1.7 mg, to reach a maintenance dose of 2.4 mg once weekly after 16 weeks is recommended 3, 5

Gradual dose titration is essential to minimize gastrointestinal adverse effects, and clinical judgment should guide adjustments to the titration schedule based on individual response, tolerance, and adverse effects 3, 4
The American College of Cardiology suggests that some patients may achieve strong responses at submaximal doses and could continue at that dose long-term 3, 4

Semaglutide should not be used with other GLP-1 receptor agonists or dipeptidyl peptidase-4 inhibitors, and may delay gastric emptying, potentially impacting absorption of oral medications requiring rapid onset 3, 4
The American College of Cardiology recommends using semaglutide with caution when combined with insulin or insulin secretagogues due to hypoglycemia risk, and monitoring and adjusting doses of concurrent medications as clinically indicated 3, 7

Gastrointestinal effects, such as nausea, vomiting, and diarrhea, are the most common adverse effects, typically transient during dose escalation, and slow titration helps minimize these effects 3, 4, 5, 8
Hypoglycemia risk is very low when used as monotherapy but increases when combined with insulin or insulin secretagogues 3, 7

Weight regain occurs after discontinuation, suggesting the need for long-term use for sustained weight management, and cardiovascular benefits have been demonstrated with semaglutide treatment in patients with established cardiovascular disease 5, 6, 8